contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Analyst

Antti Siltanen

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

In an episode of the Yle Areena series “Elossa” (Alive), 63-year-old Teresa shares her experiences with chronic neuropathic pain. She suffers from CRPS II pain (complex regional pain syndrome), which began after a surgical complication. Teresa has lived with continuous, widespread pain for over 30 years, and long-term pain has also significantly impacted her mental health. The episode highlights the activities of the neuromodulation unit at Oulu University Hospital and the use of nTMS (navigated Transcranial Magnetic Stimulation) treatment as part of Teresa’s care. Teresa undergoes nTMS treatments approximately every one and a half weeks, and the episode describes the practical implementation of the treatment and its significance in her holistic care. Psychiatrist Saana Karttunen (OYS) estimates that neuromodulation therapies are currently underutilized. The stigma associated with both depression and brain stimulation treatments can prevent patients from seeking therapies that could benefit them. Teresa aptly describes the overall effect of the treatment: “When mental well-being is supported, a better response to pain treatment is achieved – and vice versa. When pain is balanced, the mind is also brighter.” The episode offers a valuable perspective on how chronic pain and mental health are intertwined, and why multidisciplinary, individually tailored treatment is crucial in managing severe and long-term symptoms. Watch the episode on Yle Areena: LinkedIn This week, you can also meet us at the Finnish Pain Research Association’s jubilee symposium in Helsinki – welcome to exchange greetings and discuss the future of pain management in person! #Elossa #neuromodulation #nTMS #chronicpain #CRPS #mentalhealth healthcare #researchedtechnology                   LinkedIn              #elossa #neuromodulaatio #ntms #krooninenkipu #crps #mielenterveys...    Yle Areenassa katsottavassa Elossa-sarjan jaksossa 63‑vuotias Teresa kertoo kokemuksistaan kroonisen neuropaattisen kivun kanssa.   Hän sairastaa CRPS II ‑kipua (monimuotoinen paikallinen kipuoireyhtymä), joka sai alkunsa leikkauskomplikaation...

An interesting Alz article from Christin Glorioso. Christin represents a newer way of thinking in Alz research, where prevention is also a goal. The article gives a quick glance at where we are with new drug therapies, and where we are with various device therapies (these are in relation to the FDA). The Alzheimer’s Pipeline Is Finally Catching Up to the Biology Here’s a section that will be particularly interesting to those of us following Nexstim: “The approaches most likely to succeed and why: Sinaptica’s personalized rTMS is a device program that I think has a good chance of demonstrating real efficacy at scale. I have written about TMS at length on my Substack. The Phase 2 data show 44% slowing of CDR-SB over 12 months, with statistically significant improvements across cognition, daily function, and behavioral disturbances, and no serious side effects. The key distinction from earlier TMS programs is personalization, meaning calibration to each individual’s brain anatomy and connectivity using MRI, TMS-EEG, and neuronavigation, so that stimulation actually reaches the intended target. Phase 3 has not yet launched as of early 2026, but FDA Breakthrough Device Designation is in place and active preparations are underway. A second-generation system combining TMS with transcranial electrical stimulation is now being tested in early AD in Italy, with a 70% reduction in session time“

@Antti_Siltanen had made a good overview of the number of TMS studies. The number of studies has been growing well, and surely some of them will also translate into demand for clinical devices with a delay.                   Inderes – 10 Apr 26              TMS-laitteistojen käyttö tutkimuksessa - Inderes    TMS:n käyttö tutkimuksessa kasvoi erityisesti 2010-luvulla.

Neuronetics’ CEO and CFO have both left within a short period. The company has also been incurring massive losses for a long time, so I wouldn’t be surprised if the company’s end is near. This could potentially improve Nexstim’s competitive position, especially in the US therapy market.                   stocktitan.net – 6 Apr 26              CFO exit and cost cuts at Neuronetics (NASDAQ: STIM) 2026    Neuronetics plans a 5% workforce reduction with $2.5M–$3.0M in annual savings, records $0.2M in Q2 charges, sees CFO resign May 1, 2026, and reaffirms 2026 guidance.

Another interesting review study on the possibilities and development of TMS-EEG has been conducted, and it naturally includes one of the most unpleasant diseases, Alzheimer’s.                   PubMed Central (PMC)              Clinical utility and prospective of TMS–EEG: Updated review from an...    Updated review on transcranial magnetic stimulation – electroencephalography. Summarizes technology, instrumentation, artifacts, EEG analysis and physiological principles of TMS-EEG. Surveys TMS-EEG clinical utility and provides recommendations on...                             Navigation is highlighted somewhat, along with its benefits in measurement, stimulation, and, above all, reproducibility. So, we await the results of Synaptica’s third phase.

nexstim.com              Nexstim - Nexstimin suurimmat osakkeenomistajat                              It seems even professionals are slowly finding their way here. Gerako Oy has risen to 75th place on the list. Gerako has shown good business acumen in the past, for example, achieving a 1700% return from Revenio.                   Arvopaperi – 15 Dec 19              Näillä periaatteilla perhesijoitusyhtiö Gerako onnistuu – Reveniosta reilut...    Gerako sijoittaa kuin eläkeyhtiö, ja sen päätöksiä rajoittaa vain yksi asia.

I was there! Nothing “new” came to light. The CEO gave a convincing overview and also presented the new NBS 6 device in the showroom. The buns were big, and things are generally baking well for the company .

Nexstim

Nexstim’s 2023 revenue grew to some 7 MEUR, but EBITDA was below the guidance. Thanks to good sales in late 2023, we raise our forecasts slightly. The valuation picture is moderate, but the company’s situation is also twofold.

<p>Nexstim’s 2023 revenue grew to some 7 MEUR, but EBITDA was below the guidance. Thanks to good sales in late 2023, we raise our forecasts slightly. The valuation picture is moderate, but the company’s situation is also twofold. Continued good development and license income that will start later can turn cash flow around and enable future growth investments. On the other hand, a seasonally quieter H1 can freeze moneyflows and increase the likelihood of a financing round , putting pressure on the stock.</p> <p> </p> 

	2022	23e	24e
Revenue	9.5	7.0	8.8
growth-%	48.9 %	-26.6 %	25.7 %
EBIT (adj.)	0.8	-1.1	-0.4
EBIT-% (adj.)	8.8 %	-15.6 %	-4.8 %
EPS (adj.)	0.18	-0.17	-0.07
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	22.8	neg.	neg.
EV/EBITDA	22.0	neg.	333.0

Nexstim: New year starts in a mixed atmosphere

Key Estimate Figures2024-01-03

Forum discussions